Imidazoline receptors historically referred to a family of nonadrenergic binding sites that
recognize compounds with an imidazoline moiety, although this has proven to be an …

The initial realization that agents containing an imidazoline structure may interact with a
distinct class of receptors, has led to a major class of cardiovascular agents, which now has …

Abstract Both [3 H] clonidine and [3 H] idazoxan bind to α 2 adrenoceptors. The former also
labels imidazoline receptors, and the latter non-adrenergic idazoxan binding sites. In order …

Administered alone, agmatine at doses of 0.1 or 10 mg/kg is without effect in the mouse
tailflick assay. However, agmatine enhances morphine analgesia in a dose-dependent …

Imidazoline binding sites (IBS) were proposed to be responsible for some of the
pharmacological and therapeutic activities of imidazoline and related compounds and have …

Since first introduced more than two decades ago, the research in imidazoline I 2 receptors
has been steadily increasing. This review provides an update on the current status of I 2 …

The physiopathology of non-insulin-dependent diabetes mellitus is associated with a
dysfunction in the regulation of insulin secretion. The α2-adrenoceptors have been reported …

A variety of compounds containing an imidazoline ring have the ability to stimulate insulin
secretion. Many of these also improve glycaemia in experimental models of type 2 diabetes …

Using the ligands [3 H] clonidine and [3 H] idazoxan, nonadrenergic imidazoline preferring
binding sites have been identified in a range of tissues from several species including man …

The binding of [3 H] clonidine to brainstem membrane preparations was studied in an
attempt to characterize imidazoline-sensitive, catecholamine-insensitive receptors. Human …